Role of bridging therapy during chimeric antigen receptor T cell therapy.
EJHaem
; 3(Suppl 1): 39-45, 2022 Jan.
Article
en En
| MEDLINE
| ID: mdl-35844303
ABSTRACT
Chimeric antigen receptor (CAR) T-cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in clinical practice and have demonstrated excellent outcomes to those in clinical trials. However, increased real-world use of CAR T therapy has uncovered a number of barriers that can lead to significant delays in treatment. As a result, bridging therapy has become a widely used tool to stabilize or debulk disease between leukapheresis and CAR T cell administration. Here we review the available data regarding bridging therapy, with a focus on patient selection, choice of therapy, timing of therapy, and potential pitfalls.
Texto completo:
1
Colección:
01-internacional
Idioma:
En
Revista:
EJHaem
Año:
2022
Tipo del documento:
Article